Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 123.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 139.50
  • 52 Week Low: 96.00
  • Currency: UK Pounds
  • Shares Issued: 104.77m
  • Volume: 29,935
  • Market Cap: £128.87m
  • RiskGrade: 96

Deal with Barclays    Trade now with Barclays Stockbrokers

Cello Health makes strong start to year, shareholders told

By Josh White

Date: Wednesday 09 May 2018

LONDON (ShareCast) - (Sharecast News) - Healthcare-focused advisory group Cello Health told shareholders it had made a strong start to the year on Wednesday, as they met for the company's annual general meeting.
The AIM-traded firm - known until late last month as Cello Group - said that strength looked set to continue into the second quarter, based on current visibility.

Chairman Allan Rich said that, at an operating level, Cello Health had a "robust" first quarter with good revenue growth and profit performance from Cello Health Insight and Cello Health Consulting, as well as strong results from its Cello Health Communications business in the US.

"Cello Signal has also made a good start to the year, with solid operating profit performance, helped by the restructuring of the US operations in 2017," Rich told investors.

"Signal's health communications activity has got off to a quick start to the year with several significant project wins and a good pipeline of future opportunities."

The group's balance sheet remained strong, the meeting was told, with good cash conversion so far in 2018.

It continued to assess suitable acquisitions in line with its strategic objective of further growing the Cello Health brand in the US.

"As announced on 26 April, the name of the group has changed to Cello Health to better reflect the primary strategic focus of the business on the healthcare sector," Rich explained.

"The group's markets in healthcare are large and attractive, and our position is underlined by the fact that we already work with 24 of the top 25 pharmaceutical companies globally."

Following a long period of service to the group, Rich also confirmed that two non-executive directors - Paul Hamilton and Will David - had declared their intentions to retire from the board during 2018.

"The group has commenced a search process for appropriate replacement non-executive directors and will make further announcements in due course.

"The board is confident of achieving a successful result in 2018."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 123.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 139.50
52 Week Low 96.00
Volume 29,935
Shares Issued 104.77m
Market Cap £128.87m
RiskGrade 96

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.07% below the market average64.07% below the market average64.07% below the market average64.07% below the market average64.07% below the market average
65.71% above the sector average65.71% above the sector average65.71% above the sector average65.71% above the sector average65.71% above the sector average
Price Trend
0.35% above the market average0.35% above the market average0.35% above the market average0.35% above the market average0.35% above the market average
13.51% above the sector average13.51% above the sector average13.51% above the sector average13.51% above the sector average13.51% above the sector average
Income
15.54% above the market average15.54% above the market average15.54% above the market average15.54% above the market average15.54% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
32.1% below the market average32.1% below the market average32.1% below the market average32.1% below the market average32.1% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Final Interim
Ex-Div 25-Apr-19 04-Oct-18
Paid 24-May-19 02-Nov-18
Amount 2.75p 1.10p

Trades for 16-Sep-2019

Time Volume / Share Price
14:07 15,000 @ 123.00p
14:00 5,000 @ 123.00p
08:55 84,606 @ 123.00p
08:55 84,606 @ 123.00p

Cello Health Key Personnel

CEO Mark Scott

Top of Page